1	Applying GAN-based data augmentation to improve transcriptome-based					
2	prognostication in breast cancer					
3						
4	Working title: Data augmentation for improved breast cancer prognostication					
5						
6	Cristiano Guttà ^{1, *} , Christoph Morhard ² , Markus Rehm ^{1, 3, *}					
7						
8	1 Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569					
9	Stuttgart, Germany					
10	2 ProKanDo GmbH, Elfriede-Breitenbach-Straße 38a, 71640 Ludwigsburg, Germany					
11	3 Stuttgart Research Center Systems Biology, University of Stuttgart, Nobelstrasse 15, 70569					
12	Stuttgart, Germany					
13						
14	*To whom correspondence should be addressed:					
	Prof Dr Markus Rehm Cristiano Guttà					
	Institute of Cell Biology and Immunology Institute of Cell Biology and Immunology					
	University of Stuttgart University of Stuttgart					
	Allmandring 31, 70569 Stuttgart, Germany Allmandring 31, 70569 Stuttgart, Germany					
	E-mail: <u>markus.morrison@izi.uni-stuttgart.de</u> E-mail: <u>cristiano.gutta@izi.uni-stuttgart.de</u>					
	ORCID ID 0000-0001-6149-9261					
15						
16	Abstract					
17	Established prognostic tests based on limited numbers of transcripts can identify high-risk					
18	breast cancer patients yet are approved only for individuals presenting with specific clinical					
19	features or disease characteristics. Deep learning algorithms could hold potential for					
20	stratifying patient cohorts based on full transcriptome data, yet the development of robust					
21	classifiers is hampered by the number of variables in omics datasets typically far exceeding					

the number of patients. To overcome this hurdle, we propose a classifier based on a data

23 augmentation pipeline consisting of a Wasserstein generative adversarial network (0	GAN)) with
--	------	--------

- 24 gradient penalty and an embedded auxiliary classifier to obtain a trained GAN discriminator
- 25 (T-GAN-D). Applied to 1244 patients of the METABRIC breast cancer cohort, this classifier
- 26 outperformed established breast cancer biomarkers in separating low- from high-risk patients
- 27 (disease specific death, progression or relapse within 10 years from initial diagnosis).
- 28 Importantly, the T-GAN-D also performed across independent, merged transcriptome datasets
- 29 (METABRIC and TCGA-BRCA cohorts), and merging data improved overall patient
- 30 stratification. In conclusion, GAN-based data augmentation therefore allowed generating a
- robust classifier capable of stratifying low- vs high-risk patients based on full transcriptome
- 32 data and across independent and heterogeneous breast cancer cohorts.

33

34 Introduction

35	Breast cancer is the tumor with the highest incidence in women, accounting for 2.3 million
36	new diagnoses and 685,000 deaths worldwide in 2020. According to the World Health
37	Organization, nearly eight million patients were diagnosed with breast cancer in the five years
38	before 2020, making it the most prevalent tumor disease worldwide ¹ . In current clinical
39	practice, the expression of estrogen receptor (ER), progesterone receptor (PR), and human
40	epidermal growth factor receptor 2 (HER2) is determined by immunohistochemistry (IHC),
41	with the expression patterns defining to which molecular subtype (luminal A, luminal B,
42	HER2 positive or enriched and triple-negative breast cancer) individual tumors belong.
43	Prognosis differs between these subtypes, and subtyping informs treatment plans in patients in
44	which surgical resection of the tumor alone is insufficient ² . However, substantial response
45	heterogeneities to the current standard of care treatments can be observed in populations of
46	breast cancer patients ³ , highlighting the need for additional prognostic markers that could
47	serve to identify high risk patients that could instead benefit from alternative treatments or for
48	which the burden from inefficient standard of care treatments could be avoided 4 .
49	Various multi-gene activity tests based on transcript abundance have been developed to assist
50	in the clinical management of breast cancer (e.g. Oncotype DX ⁵ , MammaPrint ^{6,7} , Prosigna
51	^{8,9} , OncoMasTR ¹⁰) and received regulatory approval as prognostic tests ¹¹ . Despite the
52	prognostic value of these assays, their use is restricted to only subsets of patients with specific
53	clinical characteristics (e.g. cancer stage, receptor or lymph node status, tumor size,
54	menopause state, age group) ^{12–14} . It would therefore be desirable if more generally applicable
55	prognostic tests based on transcriptome data could be developed.
56	The rapid advances in high-throughput sequencing technologies make tumor transcriptome
57	data from larger patient cohorts increasingly available. The accessibility of -omics databases
58	and companion clinical information now also encourages the application of deep learning
59	(DL) methods to the oncology field, with the aim of learning and extracting features within

60 large scale data that are not readily accessible by classical statistical and pattern recognition 61 approaches. It is hoped that from DL-based methods tools can be developed that can aid in further advancing cancer diagnosis, prognosis or predicting treatment efficacy in the future ¹⁵. 62 DL algorithms such as convolutional neural networks (CNN) were originally applied for 63 64 image analysis but could be successfully repurposed to take non-image objects as input, such 65 as RNA-seq data ¹⁶. One of the major pitfalls when applying DL models to transcriptome 66 datasets is the typical imbalance between the number of quantified mRNAs (high) and the number of patients (low), which can lead to overfitting when solving classification tasks ¹⁷. In 67 68 addition, low numbers of samples or patients that represent one category (e.g. good prognosis) come at the risk of capturing patterns that are not robust when applied to larger populations ¹⁸. 69 Feature selection strategies ¹⁹, under- and over-sampling ²⁰ are three strategies that may help 70 71 mitigating effects arising from imbalanced source data. An alternative strategy lies in novel 72 data augmentation approaches, such as generative adversarial networks (GANs), by which 73 source datasets can be enriched with artificially generated additional data. GANs are typically 74 applied to imaging data and are composed of two subnetworks, the generator and the 75 discriminator. While the former produces synthetic images, the latter is challenged to 76 discriminate fake vs. real images. Reiterating this process, the generator learns to produce 77 images with features that can no longer be separated from the real images by the discriminator, with these generated images then enriching the source dataset ²¹. In comparison 78 79 to other generative models, GANs are currently preferred due to their computational speed and the quality of the generated images ²². In addition, they exhibit a lower risk of overfitting 80 81 classifiers and are less susceptible to the impact of non-pertinent image features (such as brightness) when enriching training data with synthetic images ²³. For example, GANs have 82 83 been applied in the medical field to generate synthetic magnetic resonance, computed tomography or positron emission tomography images²⁴. Aside from image-data, different 84

85 GAN implementations were also successfully applied to transcriptome data for cancer

86 diagnosis 25,26 , staging 27 and subtyping 28 .

87	The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, hereafter
88	MB) ²⁹ and The Cancer Genome Atlas – Breast Invasive Carcinoma (TCGA-BRCA, hereafter
89	TCGA) ³⁰ cohorts represent two of the largest and most exhaustively annotated breast cancer
90	datasets, including, in addition to mRNA expression data, features such as patient
91	demographics, cancer staging, receptor statuses, and follow-up information such as survival
92	times. Despite not being directly interoperable due to different sequencing technologies, these
93	datasets can serve as use cases to test new DL-based prognostication approaches.
94	In this study, we therefore set out to develop a prognostication framework that used the
95	trained discriminator of a GAN architecture as a standalone classifier and compared its
96	performance to classical breast cancer biomarkers and a classical CNN.
97	
98	Materials and methods
99	Data integration
99 100	Data integration The METABRIC (MB) dataset was used to develop the prototype network implementation.
100	The METABRIC (MB) dataset was used to develop the prototype network implementation.
100 101	The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS)
100 101 102	The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS) and associated clinical records were downloaded from cbioportal.org ^{31,32} . The dataset was
100 101 102 103	The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS) and associated clinical records were downloaded from cbioportal.org ^{31,32} . The dataset was integrated with locoregional and distant recurrence information retrieved from Rueda et al. ³³
100 101 102 103 104	The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS) and associated clinical records were downloaded from cbioportal.org ^{31,32} . The dataset was integrated with locoregional and distant recurrence information retrieved from Rueda et al. ³³ and <i>Risk of Recurrence – Proliferation</i> (ROR-P) scores reported by Xia et al ⁹ . Clinical
100 101 102 103 104 105	The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS) and associated clinical records were downloaded from cbioportal.org ^{31,32} . The dataset was integrated with locoregional and distant recurrence information retrieved from Rueda et al. ³³ and <i>Risk of Recurrence – Proliferation</i> (ROR-P) scores reported by Xia et al ⁹ . Clinical records, OS, DSS and progression free interval (PFI) of the validation TCGA-BRCA cohort
100 101 102 103 104 105 106	The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS) and associated clinical records were downloaded from cbioportal.org ^{31,32} . The dataset was integrated with locoregional and distant recurrence information retrieved from Rueda et al. ³³ and <i>Risk of Recurrence – Proliferation</i> (ROR-P) scores reported by Xia et al ⁹ . Clinical records, OS, DSS and progression free interval (PFI) of the validation TCGA-BRCA cohort (TCGA) were integrated from cbioportal.org ^{31,32} and Liu et al. 2018 ³⁴ , respectively. To
100 101 102 103 104 105 106 107	The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS) and associated clinical records were downloaded from cbioportal.org ^{31,32} . The dataset was integrated with locoregional and distant recurrence information retrieved from Rueda et al. ³³ and <i>Risk of Recurrence – Proliferation</i> (ROR-P) scores reported by Xia et al ⁹ . Clinical records, OS, DSS and progression free interval (PFI) of the validation TCGA-BRCA cohort (TCGA) were integrated from cbioportal.org ^{31,32} and Liu et al. 2018 ³⁴ , respectively. To merge the mRNA expression data of the two cohorts, normalized transcriptome datasets were

	1 .1	. • •	• •	• •	•	. 1	C*	
111	and with c	mantitative	information	missing	in not	more than	tive natients	were retained,
	und with c	Juantitutive	mormanon	moonig	III IIOt	more man	m ve puttente	wore retuined,

- resulting in transcripts for m = 14042 genes. The R script used to download and rescale the
- 113 datasets is available in the Zenodo repository 36 .
- 114

115 Inclusion criteria and category definition

- Both cohorts were filtered to exclude normal-like subtype samples ^{9,37,38} and patients for
- 117 which less than 10 years of follow-up time from diagnosis were available. Low and high risk
- 118 categories were defined according to published clinical records^{8,9} as follows:
- 119 high risk patients:
- MB cohort: disease specific death, locoregional or distant recurrence event
 recorded before 10 years from initial diagnosis;
- TCGA cohort: disease specific death, progression, local recurrence or distant
 metastases before 10 years from initial diagnosis.
- low risk patients: none of the above-mentioned events recorded before 10 years from
 initial diagnosis.
- 126 In total, 1248 patients of the MB cohort (n = 567 high risk, n = 681 low risk) and 165 patients
- 127 of the TCGA cohort (n = 132 high risk, n = 33 low risk) satisfied the inclusion criteria. Four
- 128 patients from each cohort were excluded after merging due to insufficient expression data.
- 129

130 Survival analysis and accuracy

- 131 Log-rank testing was used to compare predicted low vs high risk patients over a follow-up
- time of 10 years. Kaplan-Meier (KM) survival curves were computed using GraphPad Prism
- 133 8 (GraphPad Software, San Diego, CA). The area between the curves (ABC) displayed on the
- 134 KM graphs for the pooled predictions was calculated as follows:
- Low risk AUC minus Predicted low risk AUC;
- Predicted low risk AUC minus Predicted high risk AUC;

137 - Predicted high risk AUC minus High risk AUC.

138 The ABCs values are shown on the graphs in the abovementioned order top to bottom. The

AUC was computed using GraphPad Prism 8 (GraphPad Software, San Diego, CA).

140 Univariate and multivariate hazard ratios were calculated using the function *coxph* from the

- 141 R's library *survival* (v. 3.4.0, https://www.r-project.org/).
- 142

143 GAN architecture

144 The architecture was based on a Wasserstein 39 GAN 21 with gradient penalty 40 and an

auxiliary classifier ⁴¹ as a variant of a conditional GAN implementation ⁴², yielding a AC-

146 WGAN-GP architecture. The Wasserstein loss was implemented to reduce vanishing

147 gradients and mode collapse 43 in the early phases of the training when the discriminator

148 outperformed the generator. Stability was improved by exchanging the weights clipping

approach described in Arjovsky et al.³⁹, with the gradient penalty described in Gulrajani et al.

⁴⁰. To create a conditional GAN, an auxiliary classifier network was implemented ⁴¹, resulting

in a more stable training process and reduced mode collapse compared to the standard

152 conditional GAN approach, supplying labels to both discriminator and generator 43 . A z-

vector of size 250 was fed as input for the generator. Following good training practice 44 ,

strided convolutions with step size 2, batch normalization and LeakyRELU as activation

155 function were used. Since using batch normalization in the discriminator and/or the ADAM

156 optimizer led to an unstable training process, batch normalization ⁴⁵ was only used in the

157 generator, and RMSprop was selected as the activation function. A shallow network

158 consisting of two layers in both the discriminator and the generator led to the most stable159 training process, due to the smaller number of trainable parameters compared to deeper

- 160 networks. Hyperparameters were tuned empirically, selecting 1000 epochs for the training

161 process. Three "discriminator-only" training runs were performed before each full network

training run, and the generated pictures were subsequently smoothed with a final convolution

163	layer with one filter and stride size of 1. The GAN architecture generated expression data of
164	size 144x144 when using the entire transcriptome dataset of the MB cohort alone ($m = 18543$
165	genes) and 120x120 when merging the MB and TCGA cohorts ($m = 14042$ genes). In the
166	latter setting, expression profiles with less than 14,440 transcripts were filled with random
167	values, leading to better convergence. The resulting trained GAN Discriminator (T-GAN-D)
168	was then used as an independent classifier to discriminate low and high risk patients. The
169	Python code and the input files used to generate the predictions are available in the Zenodo
170	repository ³⁶ .
171	
172	CNN architecture
172 173	CNN architecture As the performance of the CNN implemented as the GAN's discriminator showed satisfactory
173	As the performance of the CNN implemented as the GAN's discriminator showed satisfactory
173 174	As the performance of the CNN implemented as the GAN's discriminator showed satisfactory performance, a similar architecture was used as a benchmark classifier. Batch normalization
173 174 175	As the performance of the CNN implemented as the GAN's discriminator showed satisfactory performance, a similar architecture was used as a benchmark classifier. Batch normalization was employed to ensure shorter training periods and RELU was used as the activation
173 174 175 176	As the performance of the CNN implemented as the GAN's discriminator showed satisfactory performance, a similar architecture was used as a benchmark classifier. Batch normalization was employed to ensure shorter training periods and RELU was used as the activation function. A fixed training length of 1250 epochs was set due to the limited sample size and to

179 by the total number of classifications performed.

180

181 Results

182

183 The METABRIC and BRCA-TCGA cohorts lend themselves as use cases for data

184 augmentation and development of prognostication classifiers

- 185 One of the major challenges of machine learning applied to -omics data and companion
- 186 medical records is the imbalance between the high amounts of variables compared to the
- 187 limited number of patients available. Even in the case of breast cancer, one of the most
- 188 frequent and widely studied malignant neoplasms, this limitation is apparent in the two major

189	public transcriptome datasets, namely the MB cohort ($n = 1904$ patients, $m = 18543$
190	transcripts) and the TCGA cohort ($n = 1101$ patients, $m = 20532$ transcripts). This imbalance
191	is exacerbated for prognostic analyses that require long-term (10 years) follow-up information
192	and the application of further exclusion criteria (see methods), reducing cohort sizes to n =
193	1248 and $n = 165$, respectively (Fig. 1A, B). Both cohorts behaved notably different, with
194	patients in the MB cohort on average having an overall substantially better prognosis in
195	overall survival and relapse-free, progression-free or disease specific survival (Fig. 1C, D).
196	This is likely attributable to the MB dataset largely consisting of stage I and stage II patients
197	(89.5% of patients with reported disease stage at diagnosis), whereas stage III and IV patients
198	are more prominent in the TCGA dataset (40.4% of individuals with available disease stage at
199	diagnosis). Despite these differences, the high risk subgroups of both cohorts showed
200	comparable median survival times (MB = 31.9 months [Fig. 1E], TCGA = 26.3 months [Fig.
201	1F]). Due to the limited sizes of these cohorts, they lend themselves as suitably challenging
202	use-cases for applying and testing data augmentation for improving prognostication. In
203	particular, we set out to implement a classifier based on a data augmentation network for
204	improved patient stratification in the MB cohort, to subsequently validate robustness and
205	transferability by integrating the independent TCGA cohort.

206

207 A trained GAN discriminator robustly identifies low and high risk breast cancer

208 patients

To tackle the problem of data scarcity, we implemented a GAN architecture to augment transcriptomic data of the MB cohort and tested the performance of a trained discriminator in stratifying breast cancer patients. First, individual patient transcriptome profiles were rescaled and converted into arrays of pixels (**Fig. 2A i**) in order to use these images as an input for the GAN. Independent of these true patient data, the generator created images representing the

214	transcript profiles of synthetic hypothetical patients together with their category (low or high
215	risk) (Fig. 2A ii). After being exposed to a fraction of the real transcriptome images and
216	associated categories, its adversary, the discriminator network then tried to distinguish fake
217	from real transcriptome images for high or low risk patients (Fig. 2A iii). Reiterating this
218	training process over 1000 epochs, the generator learned to create realistic synthetic
219	transcriptome images for high and low risk categories, which then could be used to augment
220	the original MB cohort data. Associated characteristics of this process (discriminator loss,
221	discriminator class loss, generator loss) are shown in Supplementary Fig. 1. Using this
222	approach, the discriminator learned to identify features relevant for the risk category
223	definition, aided by the synthetic profiles that enriched the real training data at each epoch.
224	The trained GAN discriminator (T-GAN-D) resulting from this process then was used as a
225	standalone classifier to categorize images from the test fraction of the cohort into the high or
226	low risk categories (Fig. 2A iv), thus prognosticating patient outcome.
227	We first implemented and tested the T-GAN-D for its prognostic capability using follow-up
228	and mRNA expression data of the prototyping MB cohort, consisting of $n = 1248$ individuals
229	and $m = 18543$ genes. Within this cohort, we independently cross-validated (CV) five-fold
230	with randomly composed training data. Kaplan-Meier curves and log rank testing for each run
231	yielded significant class separations in 4 out of 5 iterations (Fig. 2B, Supplementary Fig.
232	2A). Pooling the results so that each patient of the MB dataset was present once in the
233	survival analysis, the T-GAN-D separated high and low risk patients with high statistical
234	significance (p-value = 2.71E-12) (Fig. 2C). To obtain a reference performance baseline, a
235	classical CNN was challenged with the same task, using the same training and test sets for
236	each iteration. The CNN yielded class separations with a p<0.05 in only two out of five
237	iterations (Fig. 2D, Supplementary Fig. 2B). In the pooled comparison, the CNN performed
238	well yet failed to outperform the T-GAN-D in separating low vs. high risk patients (Fig.2E,
239	Supplementary Table 1). These results therefore demonstrate that the reiterative learning

240	process of a GAN to train its discriminator and use it as an independent classifier provides a
241	more robust and slightly improved patient stratification than a classical DL approach.

242

243 Introducing and independent cohort improves MB patient classification

A common limitation of predictors and classifiers is their limited robustness and

transferability to independent datasets. This might arise from overfitting or overtraining

within the initial cohort but also from heterogeneity and batch effects between source

247 datasets. For validating our approach further, we therefore merged the mRNA expression data

of the MB and TCGA cohorts, which originally were quantified with bead-based microarray

technology (Illumina Human V3) or RNA-Seq (Illumina HiSeq) platforms respectively ⁴⁶, by

rescaling the expression of transcripts overlapping between the two cohorts (m = 14042). We

then retrained the discriminator using the entire TCGA data plus a fraction of the MB data

252 from the merged dataset and generated predictions on an independent subset of MB patients

253 (Fig. 3A), using five-fold cross-validation. The T-GAN-D again separated patients into low

and high-risk categories with high statistical significance (Fig. 3B, Supplementary Fig. 3A).

255 The CNN trained and tested with the same data performed similarly well (Fig. 3C,

256 Supplementary Fig. 3B). The T-GAN-D trained on the merged and reduced dataset also

showed improved accuracy when compared to all settings where both a CNN or the GAN

were trained on the full or reduced MB dataset alone (**Supplementary Table 1, 2**). Therefore,

in our setting, rescaling and converting transcriptome profiles into images was sufficient to

successfully merge the two cohorts without the need for further preprocessing steps and

allowed to stratify patients into high and low risk classes.

262

263 The T-GAN-D outperforms classical outcome predictors and accurately stratifies early

264 stage patients into risk categories

265	We next compared the performance of CNN and GAN based classifications to other
266	established clinical markers in breast cancer. These included a scoring system based on a
267	multi-transcript signature (Risk-of-recurrence - proliferation, [ROR-P]), estrogen receptor
268	status (ER), human epidermal growth factor receptor 2 status (HER2), and progesterone
269	receptor status (PR). Likewise, tumor staging was included, yet was available for only 911 out
270	of 1248 patients of the MB cohort. The hazard ratios (HR) obtained from a univariate analysis
271	were comparable for ROR-P, HER2 or tumor staging as classifiers, and similar HRs were also
272	obtained for the CNN and T-GAN-D classifiers developed from only the MB transcriptome
273	dataset (Fig. 4A). Interestingly, the T-GAN-D classifier resulting from the merged cohort data
274	returned a mean HR>2.0 (+/- 0.4), thereby surpassing all other markers. This feature was even
275	more pronounced in a multivariate analysis including ER, HER2 and PR biomarkers (Fig.
276	4B). When reducing the MB cohort to those patients for which staging information was
277	available, HRs based on staging and T-GAN-D were comparable (Fig. 4C). To test whether
278	both classifiers might be redundant, we performed a T-GAN-D based survival analysis within
279	the tumor stage I and stage II subcohorts, which dominate the MB dataset. T-GAN-D based
280	classification allowed separating high and low risk patients within both tumor stages (Fig. 4D,
281	E), indicating non-redundancy of the T-GAN-D classification to tumor staging information.
282	Taken together, these results show that training through data augmentation can enhance the
283	prognostic performance of DL classifiers, and in this case surpasses individual classical
284	biomarkers. In addition, the T-GAN-D performed well in prognostication of early stage breast
285	cancer cases.

286

287 The T-GAN-D stratifies TCGA patients despite these being scarcely represented

288	After observing that introducing TCGA patients into the training set of the T-GAN-D did not
289	degrade, but improved the stratification of MB patients, we tested the performance of the
290	classifier on the smaller TCGA dataset. To do this, we trained the discriminator using the
291	entire MB data plus a fraction of the TCGA data from the merged dataset and generated
292	predictions on an independent subset of TCGA patients (Fig. 5A), using five-fold cross-
293	validation. The T-GAN-D correctly predicted 78% of the cases (Fig. 5B, Supplementary
294	Fig. 4, Supplementary Table 3). In contrast, when trained on the MB dataset alone, the T-
295	GAN-D was not able to separate high and low risk patients (Fig. 5C, Supplementary Fig. 4),
296	achieving an overall accuracy of only 43% (Supplementary Table 3). Therefore, the addition
297	to the training set of a comparably small number of TCGA patients ($n = 129$) to the larger MB
298	cohort (n = 1244) was sufficient to drastically improve the performance of the T-GAN-D
299	predicting TCGA patient outcome. This demonstrates that even if the training set is largely
300	dominated by patients belonging to one cohort, the introduction of a limited number of
301	samples of a second, differently balanced dataset appears sufficient to possibly capture
302	relevant patterns that contribute to achieving improved prognostic performance.

303

304 Discussion

305 The increasing availability and routine acquisition of large scale genomic data encourage the 306 repurposing and application of AI to the field of oncology in order to identify novel means for improved and personalized prediction of prognosis ⁴⁷. In this study, we developed a DL-based 307 308 tool to stratify high vs. low risk breast cancer patients according to full transcriptome profiles. Using the MB and TCGA cohorts as use cases, we converted expression data into images and 309 310 used the trained discriminator of our GAN architecture as a standalone prognostic classifier. 311 Our results show that the T-GAN-D performed better than classical outcome predictors and 312 maintained robust performance when merging the two cohorts.

313 AI has already been applied to breast cancer based on different classes of data, to inform diagnosis, treatment planning and prognosis ^{48,49}. For example, pattern recognition and data 314 315 augmentation proved to be promising approaches to assist in generating accurate diagnoses from mammography images ^{50,51}. Transcriptome data were also employed to develop ML-316 317 based analysis pipelines for breast cancer subtyping, diagnosis, patient stratification and 318 identification of altered pathways ⁵², and these techniques may improve the accuracy of 319 cancer prognosis in the future. However, shortcomings must be taken into account, as 320 applicable also to currently available breast cancer datasets. When dealing with low sample 321 size - high dimension datasets such as the MB and TCGA cohorts, common DL classification algorithms such as neural networks may be prone to overfitting ⁵³. Multi-gene signatures 322 323 based on the expression of a lower number of transcripts may circumvent this problem, but are applicable only to subsets of patients with specific clinical characteristics ¹¹⁻¹⁴. To tackle 324 325 these problems, we aimed at developing a more universally applicable algorithm that takes 326 advantage of GAN's data augmentation and generalizing capability. In our training strategy, 327 the T-GAN-D was exposed not only to a subset of original data, but also to the synthetic 328 patients generated by the generator in each epoch. This approach for the augmentation of 329 training data was demonstrated before to aid a discriminator in learning hidden features and correlations ^{54,55}. When compared to a classic CNN, the T-GAN-D showed comparable, yet 330 331 slightly improved performance. Other GAN implementations have been applied to the MB or TCGA cohorts in the past, addressing different aims such as the generation of missing data ⁵⁶, 332 the identification of multi -omics signatures ⁵⁷ and prognostication ⁵⁸. While showing 333 334 encouraging results, these prior works limited the follow up time to 5 years and focused on 335 death events only. Besides considering longer follow up times, the inclusion of progression or 336 recurrence events in the class definition can be considered a more exhaustive assessment of a 337 patient's risk category, since OS or DSS alone may be insufficient especially in early stage screenings ⁵⁹. In addition, short follow up times were shown to affect the prognostication 338

performance of ML algorithms leading to low sensitivity, mostly due to the insufficient
 occurrence of recurrence or death events ⁶⁰.

341 We demonstrated that the conversion of transcriptome profiles into images allowed the 342 integration of independent transcriptome datasets. To date, the majority of gene expression 343 databases cannot be directly integrated due to different sequencing technologies, protocols or 344 batch effects, with the consequence of producing merely qualitative results in a meta-analysis fashion or unveiling evidences that remain cohort-specific ⁶¹. To test if our conversion 345 346 strategy could allow a straightforward integration of heterogenous datasets, we challenged the 347 T-GAN-D in assessing the risk category of MB patients, training the network with a subset of 348 MB patients plus the entire TCGA cohort. Introducing patients belonging to a different cohort 349 improved the performance of the classifier, which in our case outperformed established clinical biomarkers and a published ROR-P signature ⁹ in uni- and multi-variate analyses. 350 351 The T-GAN-D classifier also stratified early stage breast cancer patients into low and high 352 risk groups, even though no additional factors such as treatment regimens, age, subtype or 353 other clinical features were considered when composing the training datasets. Early stage 354 patients expected to experience recurrence or progression may benefit from more frequent 355 screenings, yet it remains to be assessed if the transcriptome-based classifier operates 356 independently of or correlates with other established risk factors. 357 High accuracy in predicting the risk class of the smaller and imbalanced TCGA cohort was 358 achieved when training the T-GAN-D with a subset of TCGA patients plus the whole MB 359 dataset. Classical ML algorithms (SVM and random forest, among others) were also shown to 360 benefit from the combination of TCGA RNA-Seq and MB microarray data, which in a previous study improved 5 years OS prognostication ⁶², but lead to misleadingly high 361 362 accuracy due to highly imbalanced classes. Taken together, our results suggest that the T-363 GAN-D remains robust when merging cohorts differently balanced between positive and 364 negative outcomes, and that the network is still able to capture relevant risk patterns when one

365 cohort is heavily underrepresented in the training dataset. Therefore, our classification
366 framework may allow the integration of new, smaller datasets, lending itself as a suitable
367 prototype for generating prospective personalized outcome predictions for scarce *de novo*368 data.

369 In conclusion, our proof-of-concept study represents an avenue for developing a scalable data 370 augmentation-based tool that could be a stepping stone towards individualized prognosis in 371 the future. Molecular high throughput techniques are increasing in quality, resolution and 372 amount of data produced and are more and more commonly captured in clinical research and 373 diagnostic environments. It was estimated that within the next decade, between 2 and 40 exabytes of genomic data will be generated every year ⁶³, with large quantities being related 374 375 to human health and disease. GAN-based approaches therefore could become a meaningful 376 approach to exploit such data for the benefit of patients. In addition, -omics domains other 377 than transcriptomics likewise have the potential to enter the clinical arena as part of routine 378 analytical practice, including proteome, metabolome or lipidome data. Such data classes can readily be integrated with clinical-pathological information ⁶⁴, and could be processed with 379 380 the assistance of GAN based approaches to improve patient-tailored interventions or 381 prognostication.

382

383 Acknowledgements

MR and CG receive funding by the Deutsche Forschungsgemeinschaft (DFG, German
Research Foundation) under Germany's Excellence Strategy - EXC 2075 – 390740016 and
acknowledge the support by the Stuttgart Center for Simulation Science (SimTech).

387

388 **References**

389 1. Breast cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/breast-

390 cancer. (Accessed: 30th August 2022)

- 391 2. Yersal, O. & Barutca, S. Biological subtypes of breast cancer: Prognostic and
- 392 therapeutic implications. World J. Clin. Oncol. 5, 412 (2014).
- 393 3. Turashvili, G. & Brogi, E. Tumor heterogeneity in breast cancer. Front. Med. 4, 227 394 (2017).
- 395 4. Cardoso, F. et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage 396 Breast Cancer. N. Engl. J. Med. 375, 717–729 (2016).
- 397 5. Syed, Y. Y. Oncotype DX Breast Recurrence Score[®]: A Review of its Use in Early-

398 Stage Breast Cancer. Mol. Diagnosis Ther. 24, 621–632 (2020).

- 399 6. Van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast 400 cancer. Nat. 2002 4156871 415, 530-536 (2002).
- Arc, M. et al. A Gene-Expression Signature as a Predictor of Survival in Breast

402 Cancer. https://doi.org/10.1056/NEJMoa021967 347, 1999–2009 (2002).

8. 403 Bernard, P. S. et al. Supervised risk predictor of breast cancer based on intrinsic

404 subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).

401

7.

- 405 9. Xia, Y., Fan, C., Hoadley, K. A., Parker, J. S. & Perou, C. M. Genetic determinants of
- 406 the molecular portraits of epithelial cancers. *Nat. Commun. 2019 101* **10**, 1–13 (2019).
- 407 10. Buus, R. et al. Validation of the OncoMASTR risk score in estrogen receptor-
- 408 positive/HER2-negative patients: A TransATAC study. Clin. Cancer Res. 26, 623-631 409 (2020).
- 410 Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L. & Hortobágyi, G. N. 11.
- 411 Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer.
- 412 Oncologist 13, 477–493 (2008).
- 413 12. Yao, K., Tong, C. Y. & Cheng, C. A framework to predict the applicability of
- 414 Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer
- 415 prognostic prediction. Sci. Reports 2022 121 12, 1–11 (2022).
- 416 13. Kelly, C. M. et al. Comparison of the prognostic performance between OncoMasTR

- 417 and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative,
- 418 lymph node-negative breast cancer.
- 419 *https://doi.org/10.1200/JCO.2018.36.15_suppl.12074* **36**, 12074–12074 (2018).
- 420 14. Jensen, M. B. et al. The Prosigna gene expression assay and responsiveness to adjuvant
- 421 cyclophosphamide-based chemotherapy in premenopausal high-risk patients with
- 422 breast cancer. *Breast Cancer Res.* **20**, (2018).
- Tran, K. A. *et al.* Deep learning in cancer diagnosis, prognosis and treatment selection. *Genome Med. 2021 131* 13, 1–17 (2021).
- 425 16. Sharma, A., Vans, E., Shigemizu, D., Boroevich, K. A. & Tsunoda, T. DeepInsight: A
- 426 methodology to transform a non-image data to an image for convolution neural
- 427 network architecture. *Sci. Reports 2019 91* **9**, 1–7 (2019).
- Liu, R. & Gillies, D. F. Overfitting in linear feature extraction for classification of
 high-dimensional image data. *Pattern Recognit.* 53, 73–86 (2016).
- 430 18. Barandela, R., Valdovinos, R. M., Salvador Sánchez, J. & Ferri, F. J. The imbalanced
- 431 training sample problem: under or over sampling? *Lect. Notes Comput. Sci. (including*

432 Subser. Lect. Notes Artif. Intell. Lect. Notes Bioinformatics) **3138**, 806–814 (2004).

- 433 19. Raghu, V. K., Ge, X., Chrysanthis, P. K. & Benos, P. V. Integrated Theory- and Data-
- driven Feature Selection in Gene Expression Data Analysis. *Proceedings. Int. Conf. Data Eng.* 2017, 1525 (2017).
- Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE: Synthetic
 Minority Over-sampling Technique. *J. Artif. Intell. Res.* 16, 321–357 (2011).
- 438 21. Goodfellow, I. *et al.* Generative Adversarial Networks. *Commun. ACM* 63, 139–144
 439 (2014).
- Shorten, C. & Khoshgoftaar, T. M. A survey on Image Data Augmentation for Deep
 Learning. *J. Big Data* 6, 1–48 (2019).
- 442 23. Bowles, C. et al. GAN Augmentation: Augmenting Training Data using Generative

443		Adversarial Networks. (2018). doi:10.48550/arxiv.1810.10863
444	24.	Li, X. et al. When medical images meet generative adversarial network: recent
445		development and research opportunities. Discov. Artif. Intell. 2021 11 1, 1-20 (2021).
446	25.	Xiao, Y., Wu, J. & Lin, Z. Cancer diagnosis using generative adversarial networks
447		based on deep learning from imbalanced data. Comput. Biol. Med. 135, 104540 (2021).
448	26.	Wei, K., Li, T., Huang, F., Chen, J. & He, Z. Cancer classification with data
449		augmentation based on generative adversarial networks. Front. Comput. Sci. 2022 162
450		16 , 1–11 (2021).
451	27.	Kwon, C. H., Park, S., Ko, S. & Ahn, J. Increasing prediction accuracy of pathogenic
452		staging by sample augmentation with a GAN. PLoS One 16, e0250458 (2021).
453	28.	Yang, H., Chen, R., Li, D. & Wang, Z. Subtype-GAN: a deep learning approach for
454		integrative cancer subtyping of multi-omics data. Bioinformatics 37, 2231–2237
455		(2021).
456	29.	Mukherjee, A. et al. Associations between genomic stratification of breast cancer and
457		centrally reviewed tumour pathology in the METABRIC cohort. npj Breast Cancer
458		<i>2018 41</i> 4 , 1–9 (2018).
459	30.	The Cancer Genome Atlas Program - NCI. Available at:
460		https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga.
461		(Accessed: 30th August 2022)
462	31.	Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles
463		using the cBioPortal. Sci. Signal. 6, (2013).
464	32.	Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring
465		multidimensional cancer genomics data. Cancer Discov. 2, 401–4 (2012).
466	33.	Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive
467		genomic subgroups. Nature 567, 399-404 (2019).
468	34.	Liu, J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-

469		Quality Survival Outcome Analytics. Cell 173, 400-416.e11 (2018).
470	35.	Gendoo, D. M. A. et al. MetaGxData: Clinically Annotated Breast, Ovarian and
471		Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene
472		Signature. Sci. Rep. 9, (2019).
473	36.	Guttà, C., Morhard, C. & Rehm, M. T-GAN-D: a GAN-based classifier for breast
474		cancer prognostication. (2022). doi:10.5281/ZENODO.7151831
475	37.	Troester, M. A. et al. Racial Differences in PAM50 Subtypes in the Carolina Breast
476		Cancer Study. JNCI J. Natl. Cancer Inst. 110, 176–182 (2018).
477	38.	Sweeney, C. et al. Intrinsic subtypes from PAM50 gene expression assay in a
478		population-based breast cancer cohort: Differences by age, race, and tumor
479		characteristics. Cancer Epidemiol. Biomarkers Prev. 23, 714 (2014).
480	39.	Arjovsky, M., Chintala, S. & Bottou, L. Wasserstein GAN. (2017). Available at:
481		https://arxiv.org/abs/1701.07875v3. (Accessed: 1st March 2022)
482	40.	Gulrajani, I., Ahmed, F., Arjovsky, M., Dumoulin, V. & Courville, A. Improved
483		Training of Wasserstein GANs. Adv. Neural Inf. Process. Syst. 2017-December, 5768-
484		5778 (2017).
485	41.	Odena, A., Olah, C. & Shlens, J. Conditional Image Synthesis With Auxiliary
486		Classifier GANs. 34th Int. Conf. Mach. Learn. ICML 2017 6, 4043-4055 (2016).
487	42.	Mirza, M. & Osindero, S. Conditional Generative Adversarial Nets. (2014). Available
488		at: https://arxiv.org/abs/1411.1784v1. (Accessed: 1st March 2022)
489	43.	Kodali, N., Abernethy, J., Hays, J. & Kira, Z. On Convergence and Stability of GANs.
490		(2017). Available at: https://arxiv.org/abs/1705.07215v5. (Accessed: 1st March 2022)
491	44.	Radford, A., Metz, L. & Chintala, S. Unsupervised Representation Learning with Deep
492		Convolutional Generative Adversarial Networks. 4th Int. Conf. Learn. Represent. ICLR
493		2016 - Conf. Track Proc. (2015).
494	45.	Ioffe, S. & Szegedy, C. Batch Normalization: Accelerating Deep Network Training by

- 495 Reducing Internal Covariate Shift. 32nd Int. Conf. Mach. Learn. ICML 2015 1, 448–
- 496 456 (2015).
- 497 46. Craven, K. E., Gökmen-Polar, Y. & Badve, S. S. CIBERSORT analysis of TCGA and
- 498 METABRIC identifies subgroups with better outcomes in triple negative breast cancer.
- 499 *Sci. Reports 2021 111* **11**, 1–19 (2021).
- 500 47. Wallis, C. How Artificial Intelligence Will Change Medicine. *Nature* **576**, S48 (2019).
- 501 48. Zhang, C. *et al.* Cancer diagnosis with DNA molecular computation. *Nat. Nanotechnol.*502 2020 158 15, 709–715 (2020).
- 503 49. Jia, D. et al. Breast Cancer Case Identification Based on Deep Learning and
- 504 Bioinformatics Analysis. *Front. Genet.* **12**, 767 (2021).
- 505 50. McKinney, S. M. *et al.* International evaluation of an AI system for breast cancer
 screening. *Nat. 2020 5777788* 577, 89–94 (2020).
- 507 51. Desai, S. D., Giraddi, S., Verma, N., Gupta, P. & Ramya, S. Breast Cancer Detection
- 508 Using GAN for Limited Labeled Dataset. Proc. 2020 12th Int. Conf. Comput. Intell.
- 509 *Commun. Networks, CICN 2020* 34–39 (2020). doi:10.1109/CICN49253.2020.9242551
- 510 52. Liñares-Blanco, J., Pazos, A. & Fernandez-Lozano, C. Machine learning analysis of
 511 TCGA cancer data. *PeerJ Comput. Sci.* 7, 1–47 (2021).
- 512 53. Liu, B., Wei, Y., Zhang, Y. & Yang, Q. Deep neural networks for high dimension, low
- sample size data. in *IJCAI International Joint Conference on Artificial Intelligence*
- 514 2287–2293 (2017). doi:10.24963/ijcai.2017/318
- 515 54. He, K., Zhang, X., Ren, S. & Sun, J. Delving deep into rectifiers: Surpassing human-
- level performance on imagenet classification. in *Proceedings of the IEEE International Conference on Computer Vision* 2015 Inter. 1026–1034 (2015).
- 517 *Conference on Computer Vision* **2015 Inter**, 1026–1034 (2015).
- 518 55. Shams, S., Platania, R., Zhang, J., Kim, J. & Park, S. J. Deep generative breast cancer
- 519 screening and diagnosis. in *Lecture Notes in Computer Science (including subseries*
- 520 *Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics*) **11071**

- 521 **LNCS**, 859–867 (Springer Verlag, 2018).
- 522 56. Arya, N. & Saha, S. Generative Incomplete Multi-View Prognosis Predictor for Breast
- 523 Cancer: GIMPP. *IEEE/ACM Trans. Comput. Biol. Bioinforma.* 1–1 (2021).
- 524 doi:10.1109/TCBB.2021.3090458
- 525 57. Kim, M., Oh, I. & Ahn, J. An Improved Method for Prediction of Cancer Prognosis by
- 526 Network Learning. *Genes (Basel)*. 9, 1. 11 (2018).
- 527 58. Hsu, T. C. & Lin, C. Generative Adversarial Networks for Robust Breast Cancer
- 528 Prognosis Prediction with Limited Data Size. *Proc. Annu. Int. Conf. IEEE Eng. Med.*
- 529 Biol. Soc. EMBS 2020-July, 5669–5672 (2020).
- 530 59. Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V. & Fotiadis, D. I.
- 531 Machine learning applications in cancer prognosis and prediction. *Comput. Struct.*
- 532 *Biotechnol. J.* **13**, 8–17 (2015).
- 533 60. Boeri, C. *et al.* Machine Learning techniques in breast cancer prognosis prediction: A
 534 primary evaluation. *Cancer Med.* 9, 3234 (2020).
- 535 61. Carnielli, C. M. et al. Combining discovery and targeted proteomics reveals a
- prognostic signature in oral cancer. *Nat. Commun.* **9**, 3598 (2018).
- 537 62. Dubourg-Felonneau, G. et al. A Framework for Implementing Machine Learning on
- 538 Omics Data. (2018). doi:10.48550/arxiv.1811.10455
- 539 63. Stephens, Z. D. et al. Big Data: Astronomical or Genomical? PLoS Biol. 13, (2015).
- 540 64. Karczewski, K. J. & Snyder, M. P. Integrative omics for health and disease. *Nat. Rev.*541 *Genet.* 19, 299 (2018).
- 542
- 543

544 Figure legends

545 Fig. 1. MB and TCGA patient demographics and survival

546 (A) Patients demographics of the MB subcohort. (B) Patients demographics of the TCGA

547	subcohort. (C) Overall and (D) relapse-free, progression-free or disease specific survival of
548	the MB and TCGA cohorts. (E) Kaplan Meier curves comparing low vs high risk patients of

- the MB and (\mathbf{F}) the TCGA cohorts.
- 550

551 Fig. 2. The T-GAN-D robustly stratifies low and high risk breast cancer patients

- 552 (A) Workflow of the data processing, including the schematics of the generator network and
- its adversary, the discriminator network. Together these result in an AC-WGAN-GP
- architecture. After the conversion of patient transcriptome profiles into images, 4/5 of the MB
- dataset was used to train the GAN's discriminator. After 1000 epochs, the trained
- discriminator was used as a standalone classifier to separate the remaining 1/5 patients of the
- 557 dataset into low and high risk categories. (B) Kaplan-Meier curves separating low vs. high
- risk patients as predicted with the T-GAN-D (iteration 1 of the 5-fold CV shown as
- representative). (C) Kaplan-Meier curves generated pooling the category predictions obtained
- 560 for all patients of the MB dataset after five independent CV runs. (**D**) Separation of low vs.
- high risk patients predicted with a classical CNN on the same subset used in **B** and (E)
- 562 comparison obtained pooling the predictions of five independent CV runs. The area between
- the curves (ABC) between Low risk (blue dashed line) and Predicted low risk (solid blue
- line), Predicted low risk and Predicted high risk (solid red line), Predicted high risk and High
- risk groups (dashed red line) are shown top to bottom in **D** and **E**.
- 566

567 Fig. 3. Introducing the independent TCGA cohort improves MB patient classification

(A) Schematic representing the training strategy: rescaled data from the entire TCGA cohort
were merged with 4/5 of the MB cohort to train the T-GAN-D, which was subsequently used
to predict the risk class of the remaining 1/5 of MB patients. The process was iterated 5 times.
(B) Kaplan-Meier curves based on the pooled predictions of the T-GAN-D trained on both
cohorts. (C) Kaplan-Meier curves separating low vs. high risk patients predicted with the

	573	CNN that was	s trained after	merging the	MB and	the TCGA	cohorts.	The area	between t	he
--	-----	--------------	-----------------	-------------	--------	----------	----------	----------	-----------	----

- 574 curves (ABC) between Low risk (blue dashed line) and Predicted low risk (solid blue line),
- 575 Predicted low risk and Predicted high risk (solid red line), Predicted high risk and high risk
- 576 groups (dashed red line) are shown top to bottom in **B** and **C**.
- 577

578 Fig. 4 The T-GAN-D outperforms classical biomarkers after merging the MB and

579 TCGA cohorts and significantly stratifies early stage MB patients

- 580 (A) Comparison of the hazard ratios (Cox model, univariate) of a multi-transcript signature
- 581 (ROR-P) and established prognostic biomarkers (ER, HER2, PR) vs. the CNN and the T-
- 582 GAN-D before and after cohort merging. (B) Multivariate Cox hazard ratio of the T-GAN-D
- compared to ROR-P and receptor status and (C) disease stage. (D) Kaplan -Meier curves of
- 584 Stage I and (E) Stage II patients stratified by the T-GAN-D into low and high risk categories.
- 585

586 Fig. 5 The T-GAN-D stratifies TCGA patients despite these being scarcely represented

587 in the merged training set

588 (A) Schematic representing the training strategy: rescaled data from the entire MB cohort 589 were merged with 4/5 of the TCGA cohort to train the T-GAN-D, which was subsequently 590 used to predict the risk class of the remaining 1/5 of TCGA patients. The process was iterated 591 5 times. (B) Stratification of the TCGA patients by T-GAN-D trained on the merged dataset 592 and (C) the MB dataset alone. Kaplan-Meier curves were generated pooling the predictions of 593 all iterations of the 5-fold CV. The area between the curves (ABC) between Low risk (blue 594 dashed line) and Predicted low risk (solid blue line), Predicted low risk and Predicted high 595 risk (solid red line), Predicted high risk and High risk groups (dashed red line) are shown top to bottom in **B** and **C**. 596

Fig. 1

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.

В


D


Α

METABRIC sub-cohort (n = 1248)


Age at diagnosis (years)	# cases	%	
<40	83	6.7	
40-49	188	15.1	
50-59	288	23.1	
60-69	392	31.4	
70-79	235	18.8	
80+	62	5.0	
Disease Stage	# cases	%	
Stage I	303	24.3	
Stage II	514	41.2	
Stage III	88	7.1	
Stage IV	8	0.6	
Not available	335	26.8	
Survival (months) Median		ian	
Overall survival	163.2		
Relapse or disease specific death	160	160.2	


С













BRCA-TCGA sub-cohort (n = 165)

BRCA-ICGA sub-conort (n = 165)					
Age at diagnosis (years)	# cases	%			
<40	20	12.1			
40-49	38	23.0			
50-59	29	17.6			
60-69	44	26.7			
70-79	22	13.3			
80+	12	7.3			
Disease Stage	# cases	%			
Stage I	22	13.3			
Stage II	72	43.6			
Stage III	50	30.3			
Stage IV	14	8.5			
Not available	7	4.2			
Survival (months)	Median				
Overall survival	92				
Progression or disease specific death	35	.5			










Fig. 2

(which was not certified by pee review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license .







Time to relapse or disease specific death (months)

Time to relapse or disease specific death (months)

Fig. 4

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.





Time to progression or disease specific death (months)

Time to progression or disease specific death (months)